Highlights from the Q3 2008 review of pharmaceutical and biotechnology dealmaking: Financing dollar volume was more than twice that of Q2 with 105 deals bringing in over $4.4 billion, but not one IPO to be found. M&A dollars also nearly doubled to $23 billion in the third quarter--versus the previous three months--and of the 26 transactions with known values, more than half were over $100 million. Alliances saw activity focused primarily in two areas: drug delivery and large molecules, each category with 16 deals apiece. Total potential deal value (for the 43 alliances with known values) reached $4.5 billion, over one and a half times that of the previous quarter.
In this issue, we present another installment of our quarterly
review of pharmaceutical/biotechnology dealmaking—for the
third quarter of 2008. Our data come from FDC-Windhover's
Strategic Transactions database.
Amanda Micklus and Maureen Riordan
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
